Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;2(4):535-40.

Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions

Khaled Albouaini  1 , Mohammed Andron, Albert Alahmar, Mohaned Egred
Affiliations
Review

Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions

Khaled Albouaini et al. Int J Chron Obstruct Pulmon Dis. 2007.

Abstract

The mortality and incidence of chronic obstructive pulmonary disease (COPD) and coronary heart disease increase with age. Despite the clear evidence of beta blockers (BBs) effectiveness, there is a general reluctance to use them in patients with COPD due to a perceived contraindication and fear of inducing adverse reactions and bronchspasm. BBs are well tolerated in patients with cardiac disease and concomitant COPD with no evidence of worsening of respiratory symptoms or FEV1, and the safety of BBs in patients with COPD has been demonstrated, but their use in this group of patients remains low. The cumulative evidence from trials and meta-analysis indicates that cardioselective BBs should not be withheld in patients with reactive airway disease or COPD. Patients with COPD have a high incidence of cardiac events necessitating careful consideration of prophylactic treatment. The benefits of beta blockade in this group appear to outweigh any potential risk of side effects according to the available evidence. In this article, we will discuss the use of BBs in patients with COPD and review the evidence for their use and safety in this group of patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Beta blockers classification. Abbreviations: ISA, intrinsic sympathomimetic activity.
See this image and copyright information in PMC

References

    1. Adam WR, Meagher EJ, Barter CE. Labetalol, beta blockers, and acute deterioration of chronic airway obstruction. Clin Exp Hypertens A. 1982;4:1419–28. - PubMed
    1. Anderson G, Jariwalla AG, Al-Zaibak M. A comparison of oral metoprolol and propranolol in patients with chronic bronchitis. J Int Med Res. 1980;8:136–8. - PubMed
    1. Beil M, Ulmer WT. Effects of a new cardioselective betaadrenergic blocker (atenolol) on airway resistance in chronic obstructive disease. Arzneim-Florsch. 1977;27:419–22. - PubMed
    1. Belli G, Topol EJ. Adjunctive pharmacologic strategies for acute MI. Contemp Intern Med. 1995;7:51–9. - PubMed
    1. Butland RJ, Pang JA, Geddes DM. Effect of beta-adrenergic blockade on hyperventilation and exercise tolerance in emphysema. J Appl Physiol. 1983;54:1368–73. - PubMed

MeSH terms

Substances